FDA approves leucovorin for rare disorder, not for autism
The Food and Drug Administration has recently approved a drug called leucovorin to treat a rare brain disorder that closely resembles autism. This medication is targeted towards individuals with cerebral folate deficiency, a condition that restricts the delivery of folate, a type of vitamin B, to the brain. The approval was granted to GSK, the original manufacturer of Wellcovorin, which is a branded version of leucovorin. It is important to note that GSK does not have plans to resume the production or marketing of Wellcovorin in the future.
This approval of leucovorin is a significant development for the approximately one in a million Americans who suffer from this rare genetic disorder. However, it also marks a shift in the FDA’s stance from previous statements made by top health officials, including President Trump, who suggested that “hundreds of thousands” of children with autism could benefit from taking the drug. The FDA has now decided to focus its review of leucovorin on uses that are supported by more substantial evidence.
While cerebral folate deficiency and autism share similarities in terms of developmental delays, it is essential to recognize that they are distinct conditions. Folinic acid, a dietary supplement, has shown promise in improving symptoms in individuals with folate deficiency. Some parents of autistic children have turned to leucovorin, which contains the same active ingredient, in an attempt to enhance their children’s communication abilities. However, results from studies on the efficacy of leucovorin have been mixed, and the largest study demonstrating its effectiveness was retracted in January.
Despite the scientific uncertainties surrounding the use of leucovorin, there has been a surge in demand for the drug among Americans. Outpatient prescriptions of leucovorin increased by 71% in the weeks following the press conference where its potential benefits for autism were highlighted. This trend underscores the strong interest and hope within the community for finding effective treatments for autism and related disorders.
It is crucial to approach the use of leucovorin with caution and to rely on evidence-based practices when considering treatment options for cerebral folate deficiency and autism. The FDA’s approval of leucovorin represents a step forward in addressing the needs of individuals with rare brain disorders, while also emphasizing the importance of rigorous scientific evaluation in determining the efficacy and safety of new treatments.
